Uvaol
Based on 1 publication(s) in Google Scholar
Uvaol, a triterpene present in olives and virgin olive oil, possesses anti-inflammatory properties and antioxidant effects. Uvaol is an orally active inducer of apoptosis in astroglioma cells. Uvaol also has anti-cancer activities. Uvaol attenuates pleuritis and eosinophilic inflammation in ovalbumin-induced allergy in mice.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.20%
- No. CAS: 545-46-0
- Fòrmula: C30H50O2
- Peso molecular:442.72
-
Almacenamiento:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Uvaol
More
Actividad biológica
Descripciòn
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | GI50 |
45 μM
Compound: 19
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 32345458] |
| A549 | IC50 |
>200 μM
Compound: 2
|
Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by Hoechst 33258 staining based fluorescence assay
Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by Hoechst 33258 staining based fluorescence assay
|
[PMID: 38718553] |
| A549 | IC50 |
>316 μM
Compound: 9
|
Antiinflammatory activity against human A549 cells assessed as inhibition of IL-1-alpha-induced ICAM1 expression treated after 1 hr before IL1alpha challenge
Antiinflammatory activity against human A549 cells assessed as inhibition of IL-1-alpha-induced ICAM1 expression treated after 1 hr before IL1alpha challenge
|
[PMID: 15730243] |
| A549 | IC50 |
>316 μM
Compound: 9
|
Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 15730243] |
| B16 | ED50 |
>50 μM
Compound: 21
|
Induction of melanogenesis in mouse B16 2F2 cells assessed as intracellular melanin content after 3 days
Induction of melanogenesis in mouse B16 2F2 cells assessed as intracellular melanin content after 3 days
|
[PMID: 12027734] |
| B16 | IC50 |
46.8 μM
Compound: 21
|
Growth inhibition of mouse B16 2F2 cells after 3 days
Growth inhibition of mouse B16 2F2 cells after 3 days
|
[PMID: 12027734] |
| CHO | EC50 |
>10 μM
Compound: Uvaol
|
Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay
Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay
|
[PMID: 19911773] |
| COS-1 | EC50 |
0 μM
Compound: Uvaol
|
Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay
Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay
|
[PMID: 19911773] |
| DLD-1 | IC50 |
>200 μM
Compound: 2
|
Cytotoxicity against human DLD-1 cells assessed as inhibition of cell growth measured after 48 hrs by Hoechst 33258 staining based fluorescence assay
Cytotoxicity against human DLD-1 cells assessed as inhibition of cell growth measured after 48 hrs by Hoechst 33258 staining based fluorescence assay
|
[PMID: 38718553] |
| HCT-116 | GI50 |
37 μM
Compound: 19
|
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 32345458] |
| HepG2 | IC50 |
214 μM
Compound: 9
|
Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay
Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay
|
[PMID: 15730243] |
| HepG2 | IC50 |
53.7 μM
Compound: 10
|
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay
|
[PMID: 28318944] |
| HT-29 | IC50 |
>10 μM
Compound: 10
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
|
[PMID: 30057155] |
| HT-29 | IC50 |
>10 μM
Compound: 10
|
Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay
Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay
|
[PMID: 30057155] |
| J774 | IC50 |
155.8 μM
Compound: 4
|
Cytotoxicity against mouse J774 cells by alamar blue assay
Cytotoxicity against mouse J774 cells by alamar blue assay
|
[PMID: 17637068] |
| KB | IC50 |
37.7 μM
Compound: 10
|
Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay
Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay
|
[PMID: 28318944] |
| Lu1 | IC50 |
53.3 μM
Compound: 10
|
Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay
Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay
|
[PMID: 28318944] |
| MCF7 | GI50 |
93 μM
Compound: 19
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 32345458] |
| MCF7 | IC50 |
58.2 μM
Compound: 10
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay
|
[PMID: 28318944] |
| MDA-MB-231 | IC50 |
>10 μM
Compound: 10
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
|
[PMID: 30057155] |
| MDA-MB-435 | IC50 |
>10 μM
Compound: 10
|
Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
|
[PMID: 30057155] |
| OVCAR-3 | IC50 |
>10 μM
Compound: 10
|
Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
|
[PMID: 30057155] |
| RAW264.7 | IC50 |
>100 μM
Compound: 1
|
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of HMGB1-induced NO production
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of HMGB1-induced NO production
|
[PMID: 34973341] |
| RAW264.7 | IC50 |
>100 μM
Compound: 1
|
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production
|
[PMID: 34973341] |
| WI-38 | IC50 |
11.8 μM
Compound: 9
|
Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay
Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay
|
[PMID: 15730243] |
| WI-38 VA13 | IC50 |
58.3 μM
Compound: 9
|
Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay
Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay
|
[PMID: 15730243] |
In Vitro
Uvaol (25-50 μM; for 6-18 h) induces morphological changes in 1321N1 astrocytoma cells in the cell morphology experiment, causing cells to contract, round up and detach from the culture support, and also alters the expression levels of cell-surface proteins ICAM-1, VCAM-1 and CD44[2].
Uvaol (1-50 μM; for 18 h) inhibits DNA synthesis in 1321N1 astrocytoma cells in the cell proliferation experiment, showing a dose-dependent growth-inhibitory effect[2].
Uvaol (25-100 μM; for 18 h) induces apoptosis in 1321N1 astrocytoma cells in the apoptosis experiment, resulting in a sub-diploid peak in the cell cycle, increasing the outer leaflet of phosphatidylserine on the cell surface, and the apoptotic rate increases in a dose-dependent manner[2].
Uvaol (25-100 μM; 0.25-6 h) activates JNK in 1321N1 astrocytoma cells in the JNK activation experiment, and the activation is the strongest at 50 μM[2].
Uvaol (5-50 μM; 6-18 h) promotes the accumulation of intracellular reactive oxygen species (ROS) and reduces the mitochondrial membrane potential in 1321N1 astrocytoma cells in the ROS production experiment[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:1321N1 astrocytoma cells
-
Concentration:1 μM, 5 μM, 25 μM, 50 μM
-
Incubation Time:18 h
-
Result:Showed a dose-dependent growth-inhibitory effect.
-
Cell Line:1321N1 astrocytoma cells
-
Concentration:5 μM, 25 μM, 50 μM, 100 μM
-
Incubation Time:18 h
-
Result:Induced apoptosis in 1321N1 astrocytoma cells.
-
Cell Line:1321N1 astrocytoma cells
-
Concentration:25 μM, 50 μM, 100 μM
-
Incubation Time:18 h
-
Result:Revealed a progressive accumulation of cells in the subdipliod phase (sub-G1) of the cycle.
-
Cell Line:1321N1 astrocytoma cells
-
Concentration:25 μM, 50 μM, 100 μM
-
Incubation Time:0.25 h, 0.5 h, 1 h, 2 h, 4 h, 6 h
-
Result:Led to the activation of JNK, with the maximum activation observed after 4 h of stimulation at 50 μM.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Swiss mice (weighing 25-30 g) with subcutaneous (s.c.) injection on days 0 and 7 with 0.2 mL of a solution containing 50 μg of Ovalbumins (OVA) (HY-W250978) adsorbed to 5 mg of aluminum hydroxide[1].
-
Dosage:100 μmol/kg, 200 μmol/kg, 500 μmol/kg (2% DMSO in sterile saline)
-
Administration:Oral administration; 60 min before antigen challenge
-
Result:Caused a significant decrease in total leukocyte accumulation.
Induced a significant reduction in the levels of this cytokine.
Chemical Information
-
No. CAS 545-46-0
-
Appearance Solid
-
Peso molecular 442.72
-
Fòrmula C30H50O2
-
Color White to off-white
-
SMILES
CC1(C)[C@@H](O)CC[C@]2(C)[C@@]3([H])CC=C4[C@]5([H])[C@@H](C)[C@H](C)CC[C@@](CO)5CC[C@](C)4[C@@](C)3CC[C@@]12[H]
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Blood Coagul Fibrinolysis
Uvaol alleviates oxidative stress induced human umbilical vein endothelial cell injury by suppressing mitogen-activated protein kinase signaling pathway. [Abstract]2024 Jul 1;35(5):248-255. PMID: 38700418
Solvente y solubilidad
In Vitro:
Ethanol : 10 mg/mL (22.59 mM; ultrasonic and warming and heat to 60°C)
DMSO : 2 mg/mL (4.52 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: 1 mg/mL (2.26 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 1 mg/mL (2.26 mM); Clear solution
This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (10.0 mg/mL) to 900 μL Corn oil, and mix evenly.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (280 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Agra LC, et al. Uvaol attenuates pleuritis and eosinophilic inflammation in ovalbumin-induced allergy in mice. Eur J Pharmacol. 2016 Jun 5;780:232-42. [Content Brief]
[2]. Martín R, et al. Natural triterpenic diols promote apoptosis in astrocytoma cells through ROS-mediated mitochondrial depolarization and JNK activation. PLoS One. 2009 Jun 22;4(6):e5975. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / Ethanol | 1 mM | 2.2588 mL | 11.2938 mL | 22.5876 mL | 56.4691 mL |
| Ethanol | 5 mM | 0.4518 mL | 2.2588 mL | 4.5175 mL | 11.2938 mL |
| 10 mM | 0.2259 mL | 1.1294 mL | 2.2588 mL | 5.6469 mL | |
| 15 mM | 0.1506 mL | 0.7529 mL | 1.5058 mL | 3.7646 mL | |
| 20 mM | 0.1129 mL | 0.5647 mL | 1.1294 mL | 2.8235 mL |
Uvaol Related Classifications
HY-N1109 Related Classifications
Powered by Bioz